Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter P Toth

Showing results (91-100 of 425) with videos related to

Pageof 43
Sort By:
Journal of Clinical Lipidology|February 5, 2011
A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial: Should ezetimibe move to the "Back of the Line" as a therapy for dyslipidemia?Peter P Toth, Kevin C Maki
Expert Opinion on Drug Safety|October 18, 2011
Drug safety evaluation of rosuvastatinPeter P Toth, Thomas D Dayspring
Current Opinion in Lipidology|July 10, 2004
Combination therapy in the management of complex dyslipidemiasMichael H Davidson, Peter P Toth
Journal of Clinical Lipidology|March 6, 2012
Polish Lipid Association--a strong response to the problem of lipid disorders in Poland and Central and Eastern EuropeMaciej Banach, Michael Davidson, Peter P Toth
Angiology|September 16, 2017
C-reactive Protein Is Associated With Prevalence of the Metabolic Syndrome, Hypertension, and Diabetes Mellitus in US AdultsMohsen Mazidi, Peter P Toth, Maciej Banach
Expert Review of Cardiovascular Therapy|August 29, 2024
Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?Sohum Sheth, Maciej Banach, Peter P Toth
Current Atherosclerosis Reports|January 12, 2013
Is the future of statins aligned with new novel lipid modulation therapies?Binh An P Phan, Peter P Toth
Archives of Medical Science : AMS|December 7, 2023
2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?Maciej Banach, Stanisław Surma, Peter P Toth, et al.
JAMA Cardiology|April 28, 2021
Statin Prescribing and Dosing-Failure Has Become an OptionLaszlo Mark, Istvan Reiber, Peter P Toth
Postgraduate Medicine|August 25, 2022
LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goalsJames Underberg, Peter P Toth, Fatima Rodriguez
Pageof 43

Showing results (91-100 of 425) with videos related to

Sort By:
Pageof 43
Journal of Clinical Lipidology|February 5, 2011
A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial: Should ezetimibe move to the "Back of the Line" as a therapy for dyslipidemia?Peter P Toth, Kevin C Maki
Expert Opinion on Drug Safety|October 18, 2011
Drug safety evaluation of rosuvastatinPeter P Toth, Thomas D Dayspring
Current Opinion in Lipidology|July 10, 2004
Combination therapy in the management of complex dyslipidemiasMichael H Davidson, Peter P Toth
Journal of Clinical Lipidology|March 6, 2012
Polish Lipid Association--a strong response to the problem of lipid disorders in Poland and Central and Eastern EuropeMaciej Banach, Michael Davidson, Peter P Toth
Angiology|September 16, 2017
C-reactive Protein Is Associated With Prevalence of the Metabolic Syndrome, Hypertension, and Diabetes Mellitus in US AdultsMohsen Mazidi, Peter P Toth, Maciej Banach
Expert Review of Cardiovascular Therapy|August 29, 2024
Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?Sohum Sheth, Maciej Banach, Peter P Toth
Current Atherosclerosis Reports|January 12, 2013
Is the future of statins aligned with new novel lipid modulation therapies?Binh An P Phan, Peter P Toth
Archives of Medical Science : AMS|December 7, 2023
2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?Maciej Banach, Stanisław Surma, Peter P Toth, et al.
JAMA Cardiology|April 28, 2021
Statin Prescribing and Dosing-Failure Has Become an OptionLaszlo Mark, Istvan Reiber, Peter P Toth
Postgraduate Medicine|August 25, 2022
LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goalsJames Underberg, Peter P Toth, Fatima Rodriguez
Pageof 43